- Kane Biotech Inc. (KNE) analysis of data from efficacy trials for STEM Animal Health Inc.’s pet oral care water additive have met the primary endpoint
- Two milestone payments to STEM from STEM’s licensing partners are dependent on positive clinical efficacy data
- In September 2020, Kane formed STEM, a joint venture with Animalcare Group plc dedicated to treating biofilm-related ailments in animals
- Animalcare has a one-third-plus one share equity interest in STEM, with the balance owned by Kane
- Kane Biotech (KNE) is up 7.69 per cent and is trading at C$0.14 at 10:39 am EST
Kane Biotech Inc. (KNE) analysis of data from efficacy trials for STEM’s pet oral care water additive have met the primary endpoint.
As previously disclosed, two milestone payments to STEM from STEM’s licensing partners are dependent on positive clinical efficacy data and certification from an industry-leading body.
STEM’s pet oral care products are scientifically formulated with Kane’s patented Coactiv+™ technology to safely break down plaque and tartar biofilm and freshen breath.
In September 2020, Kane formed STEM, a joint venture with Animalcare Group plc dedicated to treating biofilm-related ailments in animals.
STEM has a global license over Kane’s existing range of animal health oral care products. In collaboration with Animalcare, it focuses on researching and developing novel animal treatments based on biofilm targeting technology.
Animalcare has a one-third-plus one share equity interest in STEM with the balance owned by Kane.
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
It has a biotechnologies portfolio, intellectual property (52 patents and patents pending, trade secrets and trademarks) and products developed by Kane’s own biofilm research expertise and acquired from leading research institutions.
StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactive+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc.
Kane Biotech is listed on the TSX Venture Exchange under the symbol “KNE” and on the OTCQB Venture Market under the symbol “KNBIF”.
Kane Biotech (KNE) is up 7.69 per cent and is trading at C$0.14 at 10:39 am EST.
